Sun, February 24, 2013
Sat, February 23, 2013
Fri, February 22, 2013
Thu, February 21, 2013
[ Thu, Feb 21st 2013 ] - Market Wire
Inorganic Growth of Healthcare
Wed, February 20, 2013
Tue, February 19, 2013
Mon, February 18, 2013
Sun, February 17, 2013
Fri, February 15, 2013
Thu, February 14, 2013
Wed, February 13, 2013
Tue, February 12, 2013
Mon, February 11, 2013
Sun, February 10, 2013
Fri, February 8, 2013
Thu, February 7, 2013
Wed, February 6, 2013
Tue, February 5, 2013
Mon, February 4, 2013
Sun, February 3, 2013
Sat, February 2, 2013

Oramed Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com


//health-fitness.news-articles.net/content/2013/ .. nd-viewing-at-retailinvestorconferences-com.html
Published in Health and Fitness on Monday, February 11th 2013 at 7:00 GMT by Market Wire   Print publication without navigation


Oramed Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com -- NEW YORK, Feb. 11, 2013 /PRNewswire/ --

NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: [ ORMP ]) ([ http://www.oramed.com ]), a developer of oral drug delivery systems, announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing.

LINK:      [ www.retailinvestorconferences.com ]> red "register/ watch event now" button

Oramed's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching FDA-approved Phase 2 clinical trials, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 1b/2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com, created by [ BetterInvesting (NAIC) ][ PR Newswire ] and [ MUNCmedia ], has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

SOURCE Oramed Pharmaceuticals Inc.



RELATED LINKS
[ http://www.oramed.com ]

Publication Contributing Sources